약물유전체학 분자진단 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 제품별, 치료 분야별, 지역별, 경쟁별(2020-2030년)
Molecular Diagnostics In Pharmacogenomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Therapeutic Area, By Region and Competition, 2020-2030F
상품코드:1807210
리서치사:TechSci Research
발행일:2025년 08월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
약물유전체학 분자진단 약 세계 시장 규모는 2024년에 6억 8,640만 달러, 2030년에는 9억 6,932만 달러에 이를 것으로 예측되며, CAGR은 6.12%를 보일 전망입니다.
파머코유전체학의 세계 분자진단 시장은 개인 맞춤형 의료와 정밀의료 수요 증가에 힘입어 강력한 성장세를 보이고 있습니다. 개인의 유전적 체질이 약물 반응에 미치는 영향을 연구하는 약물유전체학은 약물의 효과와 안전성에 영향을 미치는 유전적 변이를 식별하는 분자진단 기술에 크게 의존하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
6억 8,640만 달러
시장 규모 : 2030년
9억 6,932만 달러
CAGR : 2025-2030년
6.12%
급성장 부문
키트 및 어세이
최대 시장
북미
분자진단은 의료진이 환자 개개인에 맞게 약물을 조정하여 부작용을 최소화하고 치료 결과를 최적화하는 데 중요한 역할을 하고 있습니다. 유망한 시장임에도 불구하고, 규제 복잡성, 데이터 프라이버시 문제, 임상 검증 강화 및 의료 전문가 교육 필요성 등의 과제에 직면해 있습니다.
주요 시장 성장 촉진요인
헬스케어 산업의 성장
주요 시장 이슈
검사 비용 상승
주요 시장 동향
소아 및 노인 인구에 집중
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 COVID-19가 세계의 약물유전체학 분자진단 시장에 미치는 영향
제5장 세계의 약물유전체학 분자진단 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
제품별(키트 및 어세이, 시약, 서비스, 기타)
치료 영역별(종양학, 신경 질환, 심혈관 질환, 면역 질환, 감염증, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 약물유전체학 분자진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제7장 유럽의 약물유전체학 분자진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 약물유전체학 분자진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
한국
일본
호주
제9장 남미의 약물유전체학 분자진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 약물유전체학 분자진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병(M&A)
제품 출시
최근 동향
제13장 혼란 : 분쟁, 팬데믹, 무역장벽
제14장 세계의 약물유전체학 분자진단 시장 : SWOT 분석
제15장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제16장 경쟁 구도
Roche Diagnostics
QIAGEN
Thermo Fisher Scientific
Illumina, Inc.
Agilent Technologies
Abbott Molecular
Genomind
OneOme
Myriad Genetics
Invitae
제17장 전략적 제안
제18장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
Global Molecular Diagnostics In Pharmacogenomics Market was valued at USD 686.40 Million in 2024 and is expected to reach USD 969.32 Million by 2030 with a CAGR of 6.12%. The global molecular diagnostics market in pharmacogenomics is experiencing robust growth, driven by the increasing demand for personalized medicine and precision healthcare. Pharmacogenomics, which studies how an individual's genetic makeup affects their response to drugs, relies heavily on molecular diagnostic technologies to identify genetic variations that influence drug efficacy and safety.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 686.40 Million
Market Size 2030
USD 969.32 Million
CAGR 2025-2030
6.12%
Fastest Growing Segment
Kits and Assays
Largest Market
North America
Molecular diagnostics play a critical role in enabling healthcare providers to tailor drug therapies to individual patients, thereby minimizing adverse drug reactions and optimizing therapeutic outcomes. Despite its promising outlook, the market faces challenges such as regulatory complexities, data privacy concerns, and the need for greater clinical validation and education among healthcare professionals.
Key Market Drivers
Growth in Healthcare Industry
The rapid growth of the healthcare industry is a pivotal driver fueling the expansion of the global molecular diagnostics in pharmacogenomics market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. Among its most significant and profitable segments are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which account for over USD 400 billion. As healthcare systems worldwide evolve to offer more personalized and effective treatments, there is an increasing demand for molecular diagnostic tools that enable tailored drug therapies based on an individual's genetic profile.
Hypertension and diabetes represent approximately 70% of all chronic disease cases. As India progresses through the third phase of the epidemiological transition characterized by degenerative, stress-related, and lifestyle-induced conditions the prevalence of chronic illnesses such as diabetes and cardiovascular diseases is rising significantly, driven in part by an ageing population. Rising prevalence of chronic and genetic disorders, coupled with the growing emphasis on precision medicine, is pushing healthcare providers and pharmaceutical companies to adopt pharmacogenomics-guided diagnostics. These diagnostics help optimize drug efficacy, minimize adverse drug reactions, and enhance overall patient outcomes, aligning with the healthcare industry's broader goals of improving quality of care and reducing costs.
Key Market Challenges
High Cost of Testing
The high cost of testing represents a significant challenge in the Global Molecular Diagnostics in Pharmacogenomics Market. Pharmacogenomic tests require sophisticated technology, specialized equipment, and skilled personnel, all of which contribute to substantial expenses. These elevated costs can limit the widespread adoption of pharmacogenomic testing, particularly in cost-sensitive healthcare systems and emerging markets.
Moreover, the financial burden associated with these tests often deters healthcare providers and patients from integrating pharmacogenomics into standard clinical practice. Although the promise of personalized medicine is compelling, the upfront investment needed for molecular diagnostics remains a critical barrier. Additionally, inconsistent reimbursement policies and limited insurance coverage across different regions exacerbate this challenge, leaving many patients to bear the cost out-of-pocket. This restricts access to pharmacogenomic testing and slows market growth.
Key Market Trends
Focus on Pediatric and Geriatric Populations
A significant emerging trend within the global molecular diagnostics in pharmacogenomics market is the growing focus on pediatric and geriatric populations. Currently, government policies on growth monitoring primarily target children under the age of five. Growth monitoring is a fundamental component of under-five clinics, where children are weighed regularly monthly during the first year, every two months in the second year, and quarterly thereafter up to the age of five to six years. These two demographic groups represent distinct patient segments with unique therapeutic needs and varying responses to medication, making personalized treatment approaches especially critical.
In pediatric care, molecular diagnostics enable precise identification of genetic factors that influence drug metabolism and efficacy in children. Given the physiological differences and developmental considerations in this population, pharmacogenomic testing helps clinicians optimize drug dosing and reduce the risk of adverse drug reactions, which are often more pronounced in younger patients.
Key Market Players
Roche Diagnostics
QIAGEN
Thermo Fisher Scientific
Illumina, Inc.
Agilent Technologies
Abbott Molecular
Genomind
OneOme
Myriad Genetics
Invitae
Report Scope
In this report, the Global Molecular Diagnostics In Pharmacogenomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Molecular Diagnostics In Pharmacogenomics Market, By Product:
Kits and Assays
Reagents
Services
Others
Molecular Diagnostics In Pharmacogenomics Market, By Therapeutic Area:
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Infectious Diseases
Others
Molecular Diagnostics In Pharmacogenomics Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Molecular Diagnostics In Pharmacogenomics Market.
Available Customizations:
Global Molecular Diagnostics In Pharmacogenomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global Molecular Diagnostics in Pharmacogenomics Market
5. Global Molecular Diagnostics in Pharmacogenomics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Kits and Assays, Reagents, Services, Others)
5.2.2. By Therapeutic Area (Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Molecular Diagnostics in Pharmacogenomics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Therapeutic Area
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Molecular Diagnostics in Pharmacogenomics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Therapeutic Area
6.3.2. Mexico Molecular Diagnostics in Pharmacogenomics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Therapeutic Area
6.3.3. Canada Molecular Diagnostics in Pharmacogenomics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Therapeutic Area
7. Europe Molecular Diagnostics in Pharmacogenomics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Therapeutic Area
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Molecular Diagnostics in Pharmacogenomics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Therapeutic Area
7.3.2. Germany Molecular Diagnostics in Pharmacogenomics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Therapeutic Area
7.3.3. United Kingdom Molecular Diagnostics in Pharmacogenomics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Therapeutic Area
7.3.4. Italy Molecular Diagnostics in Pharmacogenomics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Therapeutic Area
7.3.5. Spain Molecular Diagnostics in Pharmacogenomics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Therapeutic Area
8. Asia Pacific Molecular Diagnostics in Pharmacogenomics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Therapeutic Area
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Molecular Diagnostics in Pharmacogenomics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Therapeutic Area
8.3.2. India Molecular Diagnostics in Pharmacogenomics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Therapeutic Area
8.3.3. South Korea Molecular Diagnostics in Pharmacogenomics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Therapeutic Area
8.3.4. Japan Molecular Diagnostics in Pharmacogenomics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Therapeutic Area
8.3.5. Australia Molecular Diagnostics in Pharmacogenomics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Therapeutic Area
9. South America Molecular Diagnostics in Pharmacogenomics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Therapeutic Area
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Molecular Diagnostics in Pharmacogenomics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Therapeutic Area
9.3.2. Argentina Molecular Diagnostics in Pharmacogenomics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Therapeutic Area
9.3.3. Colombia Molecular Diagnostics in Pharmacogenomics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Therapeutic Area
10. Middle East and Africa Molecular Diagnostics in Pharmacogenomics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Therapeutic Area
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Molecular Diagnostics in Pharmacogenomics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Therapeutic Area
10.3.2. Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Therapeutic Area
10.3.3. UAE Molecular Diagnostics in Pharmacogenomics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Therapeutic Area
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Disruptions: Conflicts, Pandemics and Trade Barriers
14. Global Molecular Diagnostics in Pharmacogenomics Market: SWOT Analysis
